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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Turkish language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 466 JIA patients (13.7% systemic, 40.6% oligoarticular, 22.5% RF negative poly-arthritis, 
and 23.2% other categories) and 93 healthy children were enrolled in four centres. The JAMAR components discriminated 
well-healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, 
the Turkish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine 
clinical practice and clinical research.
Keywords Juvenile idiopathic arthritis · Disease status · Functional ability · Health-related quality of life · JAMAR
Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Turkish parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Turkish language.
Rheumatology
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from July 2012 to 
October 2014. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW); and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) sub-scales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted in 
a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Lik-
ert assumption (mean and standard deviation [SD] equiva-
lence); the second Likert assumption or equal item-scale 
correlations (Pearson r: all items within a scale should con-
tribute equally to the total score); third Likert assumption 
(item internal consistency or linearity for which each item 
of a scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core-set variables, with the addition 
of the parent assessment of disease activity and pain by the 
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Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18]. Quantitative data were reported as medians 
with first and third quartiles and categorical data as absolute 
frequencies and percentages.
The complete Turkish parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Turkish JAMAR was fully cross-culturally adapted from 
the standard English version with three forward and two 
backward translations with concordance in 119/123 transla-
tion lines (96.7%) for the parent version and 107/120 lines 
(89.2%) for the child version.
Of the 123 lines in the parent version of the JAMAR, 118 
(96%) were understood by at least 80% of the 10 parents 
tested (median = 100%; range: 20–100%); 114/120 (95%) 
lines of the patient version of the JAMAR were understood 
by at least 80% of the children (median = 100%; range: 
70–100%). Lines 10, 55, 57, 113, and 114 of parent version 
of the Turkish JAMAR and lines 9, 51, 53, 55, 107, and 
110 of the child version were modified according to parents/
children suggestions after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 468 JIA patients and 95 healthy children (total of 
563 subjects) were enrolled at five paediatric rheumatology 
centres. Two patients and two healthy children did not give 
the consent to use their data.
In the remaining 466 JIA subjects, the JIA categories 
were 13.7% with systemic arthritis, 40.6% with oligoarthri-
tis, 22.5% with RF negative poly-arthritis, 2.4% with RF 
positive poly-arthritis, 3.2% with psoriatic arthritis, 15% 
with enthesitis related arthritis, and 2.6% with undifferenti-
ated arthritis (Table 1).
A total of 555/559 (99.3%) subjects had the parent ver-
sion of the JAMAR completed by a parent (463 from parents 
of JIA patients and 92 from parents of healthy children). The 
JAMAR was completed by 364/555 (65.6%) mothers and 
191/555 (34.4%) fathers. The child version of the JAMAR 
was completed by 438/555 (78.9%) children age 6 or older. 
In addition, patients younger than 7 years, capable to assess 
their personal condition and able to read and write, were 
asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including the 
scores [median (1st–3rd quartile)] obtained for the PF, the 
PhH, the PsH sub-scales, and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses was 2.3% (1.1–3.1%).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items, whereas a reduced number of response 
choices were used for the PF item 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 1% (1–4%) for the PF and 8.5% (5–14%) 
for the HRQoL.
Floor and ceiling effect
The median floor effect was 83.2% (73.2–89.4%) for the PF 
items, 49.7% (42.8–53.1%) for the HRQoL PhH items, and 
49.9% (39.7–62.2%) for the HRQoL-PsH items. The median 
ceiling effect was 1.3% (0.6–1.7%) for the PF items, 3.0% 
(3.0-4.3%) for the HRQoL PhH items, and 2.6% (2.2–4.8%) 
for the HRQoL-PsH items. The median floor effect was 
39.5% for the pain VAS, 35.6% for the disease activity VAS, 
and 33% for the well-being VAS. The median ceiling effect 
was 2.2% for the pain VAS, 1.9% for the disease activity 
VAS and 1.5% for the well-being VAS.
Equal item‑scale correlations (second Likert 
assumption)
Pearson item-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93% of the 
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Table 1  Descriptive statistics (medians, first–third quartiles or absolute frequencies and %) for the 466 JIA patients
Data related to the JAMAR refer to the 463 JIA patients and to the 92 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA Anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. * p < 0.05, ** p < 0.001, # p < 0.0001
Systemic Oligoarthritis RF − poly-
arthritis
RF + poly-
arthritis
Psoriatic 
Arthritis
Enthesitis 
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 64 N = 189 N = 105 N = 11 N = 15 N = 70 N = 12 N = 466 N = 93
Female 35 (54.7%) 133 (70.4%) 73 (69.5%) 9 (81.8%) 7 (46.7%) 11 (15.7%) 11 (91.7%) 279 (59.9%)# 49 (52.7%)
Age at visit 10 (7.2–13.3) 7.3 (5–11) 11.3 
(7.6–14.5)
14.9 (14.4–
15.8)
13.3 
(10.3–15)
14.5 (12.2–
16.5)
15.9 (15.4–
16.4)
10.8 
(6.6–14.3)#
11.9 (9.6–
13.4)*
Age at onset 5.8 (2.4–8.9) 3.8 (1.7–7.3) 6.8 (3.8–10.8) 9.5 (7.8–13.2) 5.8 (3.2–11.4) 11.8 
(9.3–13.6)
13.9 (12.8–
14.4)
6.3 (2.7–
10.8)#
Disease duration 2.9 (1.1–6.2) 2.3 (1-4.2) 2.9 (1.5–5.4) 4.1 (1.1–6.7) 4.8 (2.8–8.6) 2.4 (1.2–4.1) 1.9 (1.1-3) 2.6 (1.2–
4.6)*
ESR 12 (9–30) 14 (8–24) 15 (10–26) 24 (19–46) 12 (9–16) 12 (6–22) 13 (10–33) 14 (8–25)
MD VAS 
(0–10 cm)
1 (0-2.5) 1.5 (0.5-4) 3.5 (1–5) 2.5 (2–6) 1 (0–3) 2 (1–4) 3.8 (3-5.3) 2 (0.5-4)#
No. swollen joints 0 (0–0) 0 (0–1) 0 (0–3) 1 (0–6) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–1)#
No. joints with 
pain
0 (0–0) 0 (0–1) 1 (0–4) 2 (0–13) 0 (0–0) 0 (0–3) 2 (0.5-4) 0 (0–2)#
No. joints with 
LOM
0 (0–1) 0 (0–1) 1 (0–2) 1 (0–2) 0 (0–0) 0 (0–1) 0 (0-0.5) 0 (0–1)#
No. active joints 0 (0–1) 1 (0–1) 1 (0–4) 2 (0–6) 0 (0–1) 0 (0–1) 0 (0-0.5) 0 (0–2)#
Active systemic 
features
9 (14.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 9 (2%)#
ANA status 0 (0%) 33 (17.5%) 10 (9.5%) 2 (18.2%) 1 (6.7%) 0 (0%) 0 (0%) 46 (9.9%)#
Uveitis 0 (0%) 25 (13.4%) 8 (7.9%) 0 (0%) 0 (0%) 4 (5.9%) 0 (0%) 37 (8.1%)*
PF Total Score 1 (0-4.5) 1 (0–3) 3 (0–9) 3 (2–10) 0 (0–4) 1 (0–4) 2.5 (1.5–14) 2 (0–5)** 0 (0–1)#
Pain VAS 0 (0-3.3) 1 (0–3) 2 (0-4.5) 2 (0–5) 0 (0-3.5) 1 (0-4.8) 4.5 (2.5–8.5) 1 (0–4)* 0 (0–0)#
Disease activity 
VAS
0 (0-2.5) 1 (0–3) 1.5 (0–4) 3.8 (0.5-5) 0.5 (0-2.5) 1 (0-3.5) 3.3 (2.8-6) 1 (0-3.5)*
Well-being VAS 1 (0-2.5) 1 (0–4) 2 (0–5) 5 (1.5–6.5) 1 (0–5) 1 (0-4.5) 4.3 (2.5–6.5) 1 (0-4.5)*
HRQoL-PhH 1 (0–4) 3 (0–5) 2 (1–5) 5 (1–5) 1 (0–4) 2 (0–4) 4 (1.5–8.5) 2 (0–5)* 0 (0–3)#
HRQoL-PsH 3 (1–5) 2 (0–4) 3 (1–5) 3 (1–8) 3 (0–6) 2 (0–5) 4 (2-6.5) 2 (1–5) 1.5 (0–3)**
HRQoL total 
score
4 (2–9) 5 (2–9) 6 (2–10) 7 (6–13) 6 (1–8) 4.5 (1–9) 9 (5.5–12) 5 (2–10) 2 (0–6)#
Pain/swell. in > 1 
joint
25 (39.1%) 118/188 
(62.8%)
74/103 
(71.8%)
8 (72.7%) 7 (46.7%) 38 (54.3%) 12 (100%) 282/463 
(60.9%)#
5/92 (5.4%)#
Morning stiff-
ness > 15 min
10 (15.6%) 29/185 
(15.7%)
27/96 (28.1%) 3/10 (30%) 3/14 (21.4%) 15/69 (21.7%) 4 (33.3%) 91/450 
(20.2%)
2/90 (2.2%)#
Subjective remis-
sion
23/63 
(36.5%)
109/177 
(61.6%)
72/93 (77.4%) 7/10 (70%) 9/14 (64.3%) 38/65 (58.5%) 10 (83.3%) 268/434 
(61.8%)#
In treatment 48/63 
(76.2%)
168/185 
(90.8%)
89/101 
(88.1%)
11 (100%) 13/14 
(92.9%)
61/67 (91%) 11 (91.7%) 401/453 
(88.5%)
Reporting side 
effects
22/48 
(45.8%)
56/162 
(34.6%)
38/86 (44.2%) 3 (27.3%) 5/12 (41.7%) 24/61 (39.3%) 6/10 (60%) 154/390 
(39.5%)
Taking medica-
tion regularly
41/47 
(87.2%)
151/163 
(92.6%)
80/87 (92%) 11 (100%) 10/13 
(76.9%)
55/61 (90.2%) 8/11 (72.7%) 356/393 
(90.6%)
With problems 
attending school
7/32 (21.9%) 19/95 (20%) 15/56 (26.8%) 1/3 (33.3%) 2/6 (33.3%) 14/47 (29.8%) 4/8 (50%) 62/247 
(25.1%)
3/81 (3.7%)#
Satisfied with dis-
ease outcome
34/61 
(55.7%)
73/180 
(40.6%)
38/97 (39.2%) 4/10 (40%) 11 (73.3%) 31/64 (48.4%) 3 (25%) 194/439 
(44.2%)
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PF items, with the exception of item 15 and for 100% of the 
HRQoL items.
Item internal consistency (third Likert assumption)
Pearson item-scale correlations were ≥ 0.4 for 100% of items 
of the PF and 100% of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.87 for PF-LL, 0.90 for PF-HW, and 
0.84 for PF-US. Cronbach’s alpha was 0.87 for HRQoL-PhH 
and 0.82 for HRQoL-PsH.
Table 2  Main psychometric characteristics between the parent and child versions of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 463/555 Child N = 348/438
Missing values (1st–3rd quartiles) 2.3% (1.1–3.1%) 1.9% (0.4–2.6%)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 83.2% 85.1%
 HRQoL PhH 49.7% 54.0%
 HRQoL-PsH 49.9% 60.1%
 Pain VAS 39.5% 34.2%
 Disease activity VAS 35.6% 36.2%
 Well-being VAS 33.0% 34.5%
Ceiling effect, median
 PF 1.3% 0.9%
 HRQoL PhH 3.0% 4.0%
 HRQoL-PsH 2.6% 2.0%
 Pain VAS 2.2% 1.1%
 Disease activity VAS 1.9% 0.6%
 Well-being VAS 1.5% 0.6%
Items with equivalent item-scale correlation 93% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Items with item-scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 100% for PF,100% for HRQoL
Cronbach’s alpha
 PF–LL 0.87 0.85
 PF–HW 0.90 0.88
 PF–US 0.84 0.79
 HRQoL–PhH 0.87 0.88
 HRQoL–PsH 0.82 0.78
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intra-class correlation
 PF total score 0.96 0.83
 HRQoL–PhH 0.78 0.94
 HRQoL–PsH 0.86 0.77
Spearman correlation with JIA core-set variables, median
 PF 0.5 0.5
 HRQoL PhH 0.5 0.5
 HRQoL-PsH 0.3 0.3
 Pain VAS 0.4 0.4
 Disease activity VAS 0.4 0.4
 Well-being VAS 0.4 0.4
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Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 18 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after 
a median of 7 days (range 7–8 days). The intra-class cor-
relation coefficients (ICC) for the PF total score showed 
an almost perfect reproducibility (ICC = 0.96). The ICC 
for the HRQoL PhH showed a substantial reproducibility 
(ICC = 0.78) and the ICC for the HRQoL-PsH showed an 
almost perfect reproducibility (ICC = 0.86).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.5 
(median = 0.5). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.53, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged from 
0.3 to 0.6 (median = 0.5), whereas for the PsH ranged from 
0.2 to 0.4 (median = 0.3). The HRQoL PhH showed the best 
correlation with the parent’s assessment of pain (r = 0.64, 
p < 0.001), while the HRQoL-PsH showed the best cor-
relation with the parent global assessment of well-being 
(r = 0.43, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity VAS 
and the physician-centred and laboratory measures were 0.4 
(0.4–0.5), 0.4 (0.4–0.5), 0.4 (0.4–0.5), respectively.
Discussion
In this study, the Turkish version of the JAMAR was cross-
culturally adapted from the original standard English version 
with three forward and two backward translations. Accord-
ing to the results of the validation analysis, the Turkish par-
ent and patient versions of the JAMAR possess satisfactory 
psychometric properties. The disease-specific components 
of the questionnaire discriminated well between patients 
with JIA and healthy controls. The PF total score and the 
HRQoL PhH revealed to be able to discriminate between 
the different JIA subtypes with the children diagnosed with 
RF negative poly-arthritis, RF positive poly-arthritis and 
undifferentiated arthritis having a higher degree of disability.
Psychometric performances were good for all domains of 
the JAMAR and the overall internal consistency was good 
for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core-set 
parameters were moderate.
The results obtained for the parent version of the 
JAMAR are very similar to those obtained for the child 
version, which suggests that children are equally reliable 
proxy reporters of their disease and health status as their 
parents. The JAMAR is aimed to evaluate the side effects 
of medications and school attendance, which are other 
dimensions of daily life that were not previously consid-
ered by other HRQoL tools. This may provide useful infor-
mation for intervention and follow-up in health care. In 
conclusion, the Turkish version of the JAMAR was found 
to have satisfactory psychometric properties and it is, thus, 
a reliable and valid tool for the multidimensional assess-
ment of children with JIA.
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